bf/NASDAQ:RXDX_icon.jpeg

NASDAQ:RXDX

Prometheus Biosciences, Inc.

  • Stock

USD

Last Close

199.74

15/06 20:00

Market Cap

9.56B

Beta: −0.60

Volume Today

1.79M

Avg: 983.04K

PE Ratio

−63.62

PFCF: −88.63

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antib...Show More

Earnings

Earnings per Share (Estimate*)

-1.5-1-0.52014-03-312015-09-302017-03-312021-03-122022-08-11

Revenue (Estimate*)

1M2M3M4M2014-03-312015-09-302017-03-312021-03-122022-08-11

*Estimate based on analyst consensus

founders

  • Scott Glenn

investors

PartnersFunding RoundInvestor NameLead Investor
Private Equity Round - Prometheus BiosciencesCowen Healthcare Investments
Private Equity Round - Prometheus BiosciencesNestlé
Private Equity Round - Prometheus BiosciencesCedars Sinai
Private Equity Round - Prometheus BiosciencesAGI Partners
Private Equity Round - Prometheus BiosciencesCormorant Capital
Private Equity Round - Prometheus BiosciencesRTW InvestmentsYes
Joy GhoshPrivate Equity Round - Prometheus BiosciencesEventideYes
Private Equity Round - Prometheus BiosciencesPoint72
Private Equity Round - Prometheus BiosciencesIrving Investors
Adam StonePrivate Equity Round - Prometheus BiosciencesPerceptive Advisors

num employees

  • 501-1000

funding rounds

Money RaisedAnnounced DateLead InvestorsTransaction NameNumber of Investors
$500M08-12-2022Post-IPO Equity - Prometheus Biosciences
$130M09-11-2020Eventide, RTW InvestmentsPrivate Equity Round - Prometheus Biosciences10
$48.1M30-06-2019Venture Round - Prometheus Biosciences
$10.1M28-11-2018Venture Round - Prometheus Biosciences
$3.7M09-10-2017Series A - Prometheus Biosciences
$260M07-01-2010Debt Financing - Prometheus Biosciences

Please Sign In To Use The Chat

The chat is only available for registered users, please sign in or create your free account.